

M45-A2
Vol. 30 No. 18
Replaces M45-A
Vol. 26 No. 19

Methods for Antimicrobial Dilution and Disk Susceptibility Testing of Infrequently Isolated or Fastidious Bacteria; Approved Guideline—Second Edition

This document provides guidance to clinical microbiology laboratories for standardized susceptibility testing of infrequently isolated or fastidious bacteria that are not presently included in CLSI documents M02 or M07. The tabular information in this document presents the most current information for drug selection, interpretation, and quality control for the infrequently isolated or fastidious bacterial pathogens included in this guideline.

A guideline for global application developed through the Clinical and Laboratory Standards Institute consensus process.



Clinical and Laboratory Standards Institute

Advancing Quality in Health Care Testing

Clinical and Laboratory Standards Institute (CLSI, formerly NCCLS) is an international, interdisciplinary, nonprofit, standards-developing, and educational organization that promotes the development and use of voluntary consensus standards and guidelines within the health care community. It is recognized worldwide for the application of its unique consensus process in the development of standards and guidelines for patient testing and related health care issues. Our process is based on the principle that consensus is an effective and cost-effective way to improve patient testing and health care services.

In addition to developing and promoting the use of voluntary consensus standards and guidelines, we provide an open and unbiased forum to address critical issues affecting the quality of patient testing and health care.

PUBLICATIONS

A document is published as a standard, guideline, or committee report.

Standard A document developed through the consensus process that clearly identifies specific, essential requirements for materials, methods, or practices for use in an unmodified form. A standard may, in addition, contain discretionary elements, which are clearly identified.

Guideline A document developed through the consensus process describing criteria for a general operating practice, procedure, or material for voluntary use. A guideline may be used as written or modified by the user to fit specific needs.

Report A document that has not been subjected to consensus review and is released by the Board of Directors.

CONSENSUS PROCESS

The CLSI voluntary consensus process is a protocol establishing formal criteria for

- The authorization of a project
- The development and open review of documents
- The revision of documents in response to comments by users
- The acceptance of a document as a consensus standard or guideline

Most documents are subject to two levels of consensus—"proposed" and "approved." Depending on the need for field evaluation or data collection, documents may also be made available for review at an intermediate consensus level.

Proposed A consensus document undergoes the first stage of review by the health care community as a proposed standard or guideline. The document should receive a wide and thorough technical review, including an overall review of its scope, approach, and utility, and a line-by-line review of its technical and editorial content.

Approved An approved standard or guideline has achieved consensus within the health care community. It should be reviewed to assess the utility of the final document, to ensure attainment of consensus (ie, that comments on earlier versions have been satisfactorily addressed), and to identify the need for additional consensus documents.

Our standards and guidelines represent a consensus opinion on good practices and reflect the substantial agreement by materially affected, competent, and interested parties obtained by following CLSI's established consensus procedures. Provisions in CLSI standards and guidelines may be more or less stringent than applicable regulations. Consequently, conformance to this voluntary consensus document does not relieve the user of responsibility for compliance with applicable regulations.

COMMENTS

The comments of users are essential to the consensus process. Anyone may submit a comment, and all comments are addressed, according to the consensus process, by the committee that wrote the document. All comments, including those that result in a change to the document when published at the next consensus level and those that do not result in a change, are addressed by the committee in an appendix to the document. Readers are strongly encouraged to comment in any form and at any time on any document. Address comments to Clinical and Laboratory Standards Institute, 940 West Valley Road, Suite 1400, Wayne, PA 19087, USA.

VOLUNTEER PARTICIPATION

Health care professionals in all specialties are urged to volunteer for participation in CLSI projects. Please contact us at customerservice@clsi.org or +610.688.0100 for additional information on committee participation.

M45-A2
ISBN 1-56238-732-4
ISSN 0273-3099

Volume 30 Number 18

Methods for Antimicrobial Dilution and Disk Susceptibility Testing of Infrequently Isolated or Fastidious Bacteria; Approved Guideline—Second Edition

James H. Jorgensen, PhD
Janet A. Hindler, MCLS, MT(ASCP)
Kathryn Bernard, MS
Diane M. Citron, M(ASCP)
Franklin R. Cockerill, III, MD
Thomas R. Fritsche, PhD, MD
Guido Funke, MD
Henry Heine, PhD

Patrick McDermott, PhD
Jean B. Patel, PhD, D(ABMM)
Paul C. Schreckenberger, PhD, D(ABMM)
John D. Turnidge, MD
David F. Welch, PhD, D(ABMM)

Abstract

If the susceptibility of a bacterial pathogen to antimicrobial agents cannot be predicted based on the identity of the organism alone, *in vitro* antimicrobial susceptibility testing of the organism isolated may be indicated. Susceptibility testing is particularly necessary in those situations in which the etiological agent belongs to a bacterial species for which resistance to commonly used antimicrobial agents has been documented, or could arise.

A variety of laboratory techniques can be used to measure the *in vitro* susceptibility of bacteria to antimicrobial agents. Clinical and Laboratory Standards Institute document M45-A2—*Methods for Antimicrobial Dilution and Disk Susceptibility Testing of Infrequently Isolated or Fastidious Bacteria; Approved Guideline—Second Edition* describes the standard microdilution and agar disk diffusion methods. It also includes a series of procedures designed to standardize test performance. The performance, applications, and limitations of the current CLSI-recommended methods are described.

The tabular information in this document presents the most current information for drug selection, interpretation, and quality control for the infrequently isolated or fastidious bacterial pathogens included in this guideline. As more information becomes available, changes will be incorporated into future revisions of this document.

Clinical and Laboratory Standards Institute (CLSI). *Methods for Antimicrobial Dilution and Disk Susceptibility Testing of Infrequently Isolated or Fastidious Bacteria; Approved Guideline—Second Edition*. CLSI document M45-A2 (ISBN 1-56238-732-4). Clinical and Laboratory Standards Institute, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA, 2010.

The Clinical and Laboratory Standards Institute consensus process, which is the mechanism for moving a document through two or more levels of review by the health care community, is an ongoing process. Users should expect revised editions of any given document. Because rapid changes in technology may affect the procedures, methods, and protocols in a standard or guideline, users should replace outdated editions with the current editions of CLSI documents. Current editions are listed in the CLSI catalog and posted on our website at www.clsi.org. If your organization is not a member and would like to become one, and to request a copy of the catalog, contact us at: Telephone: 610.688.0100; Fax: 610.688.0700; E-Mail: customerservice@clsi.org; Website: www.clsi.org



Copyright ©2010 Clinical and Laboratory Standards Institute. Except as stated below, neither this publication nor any portion thereof may be adapted, copied, or otherwise reproduced, by any means (electronic, mechanical, photocopying, recording, or otherwise) without prior written permission from Clinical and Laboratory Standards Institute ("CLSI").

CLSI hereby grants permission to each individual member or purchaser to make a single reproduction of this publication for use in its laboratory procedure manual at a single site. To request permission to use this publication in any other manner, contact the Executive Vice President, Clinical and Laboratory Standards Institute, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898, USA.

Suggested Citation

CLSI. *Methods for Antimicrobial Dilution and Disk Susceptibility Testing of Infrequently Isolated or Fastidious Bacteria; Approved Guideline—Second Edition*. CLSI document M45-A2. Wayne, PA: Clinical and Laboratory Standards Institute; 2010.

Proposed Guideline

October 2005

Approved Guideline

May 2006

Approved Guideline—Second Edition

August 2010

ISBN 1-56238-732-4

ISSN 0273-3099

Committee Membership

Area Committee on Microbiology

John H. Rex, MD, FACP
Chairholder
AstraZeneca
Cheshire, United Kingdom

Mary Jane Ferraro, PhD, MPH
Vice-Chairholder
Massachusetts General Hospital
Boston, Massachusetts, USA

Nancy L. Anderson, MMSc,
 MT(ASCP)
 Centers for Disease Control and
 Prevention
 Atlanta, Georgia, USA

Barbara Ann Body, PhD,
 D(ABMM)
 Laboratory Corporation of America
 Burlington, North Carolina, USA

Betty (Betz) A. Forbes, PhD,
 D(ABMM)
 Medical College of Virginia
 Campus
 Richmond, Virginia, USA

Thomas R. Fritsche, MD, PhD
 Marshfield Clinic
 Marshfield, Wisconsin, USA

Freddie Mae Poole, MS, MT
 FDA Center for Devices and
 Radiological Health
 Rockville, Maryland, USA

Fred C. Tenover, PhD, D(ABMM)
 Cepheid
 Sunnyvale, California, USA

John D. Turnidge, II, MD
 Women's and Children's Hospital
 North Adelaide, Australia

Advisors

Donald R. Callihan, PhD
 BD Diagnostic Systems
 Sparks, Maryland, USA

James H. Jorgensen, PhD
 University of Texas Health Science
 Center
 San Antonio, Texas, USA

Jean B. Patel, PhD, D(ABMM)
 Centers for Disease Control and
 Prevention
 Atlanta, Georgia, USA

Michael A. Pfaller, MD
 University of Iowa College of
 Medicine
 Iowa City, Iowa, USA

Thomas R. Shryock, PhD
 Elanco Animal Health
 Greenfield, Indiana, USA

Jana M. Swenson, MMSc
 Centers for Disease Control and
 Prevention
 Atlanta, Georgia, USA

Jeffrey L. Watts, PhD, RM(AAM)
 Pfizer Animal Health
 Richland, Michigan, USA

Melvin P. Weinstein, MD
 Robert Wood Johnson Medical School
 New Brunswick, New Jersey, USA

Nancy Wengenack, PhD
 Mayo Clinic
 Rochester, Minnesota, USA

Matthew A. Wikler, MD, MBA, FIDSA
 Institute for One World Health
 San Francisco, California, USA

Michael L. Wilson, MD
 Denver Health Medical Center
 Denver, Colorado, USA

Gail L. Woods, MD
 Central Arkansas Veterans Healthcare
 System
 Little Rock, Arkansas, USA

Barbara L. Zimmer, PhD
 Siemens Healthcare Diagnostics
 West Sacramento, California, USA

Subcommittee on Antimicrobial Susceptibility Testing

Franklin R. Cockerill, III, MD
Chairholder
Mayo Clinic College of Medicine
Rochester, Minnesota, USA

Matthew A. Wikler, MD, MBA,
FIDSA
Vice-Chairholder
Institute for One World Health
San Diego, California, USA

Karen Bush, PhD
 Indiana University
 Bloomington, Indiana, USA

Michael N. Dudley, PharmD, FIDSA
 Mpex Pharmaceuticals
 San Diego, California, USA

George M. Eliopoulos, MD
 Beth Israel Deaconess Medical Center
 Boston, Massachusetts, USA

Dwight J. Hardy, PhD
 University of Rochester Medical Center
 Rochester, New York, USA

David W. Hecht, MD
 Loyola University Medical Center
 Maywood, Illinois, USA

Janet A. Hindler, MCLS, MT(ASCP)
 UCLA Medical Center
 Los Angeles, California, USA

Jean B. Patel, PhD, D(ABMM)
 Centers for Disease Control and
 Prevention
 Atlanta, Georgia, USA

Mair Powell, MD, FRCP, FRCPath
 MHRA
 London, United Kingdom

Richard B. Thomson, Jr., PhD
 Evanston Hospital and The University
 of Chicago School of Medicine
 Evanston, Illinois, USA

John D. Turnidge, MD
 Women's and Children's Hospital
 North Adelaide, Australia

Melvin P. Weinstein, MD
 Robert Wood Johnson Medical School
 New Brunswick, New Jersey, USA

Barbara L. Zimmer, PhD
 Siemens Healthcare Diagnostics
 West Sacramento, California, USA

Advisors

Paul G. Ambrose, PharmD, FIDSA
ICPD/Orway Research Institute
Albany, New York, USA

Patricia A. Bradford, PhD
Novartis Institutes for Biomedical
Research
Cambridge, Massachusetts, USA

Steven D. Brown, PhD
The Clinical Microbiology Institute
Wilsonville, Oregon, USA

Karen Carroll, MD
Johns Hopkins Medical Institutions
Baltimore, Maryland, USA

Edward M. Cox, Jr., MD, MPH
FDA Center for Drug Evaluation and
Research
Rockville, Maryland, USA

William A. Craig, MD
Wm. S. Middleton Memorial VA Hospital
Madison, Wisconsin, USA

Cynthia L. Fowler, MD
bioMérieux, Inc.
Durham, North Carolina, USA

Yoichi Hirakata, MD, FJSIM, PhD
Tohoku University Graduate School
of Medicine
Sendai, Japan

Ronald N. Jones, MD
JMI Laboratories
North Liberty, Iowa, USA

Gunnar Kahlmeter, MD, PhD
ESCMID
Växjö, Sweden

Frederic J. Marsik, PhD, ABMM
FDA Center for Drug Evaluation and
Research
Silver Spring, Maryland, USA

Linda A. Miller, PhD
GlaxoSmithKline
Collegeville, Pennsylvania, USA

Harriette L. Nadler, PhD
DJA Global Pharmaceuticals, Inc.
Chadds Ford, Pennsylvania, USA

Freddie Mae Poole, MS, MT
FDA Center for Devices and
Radiological Health
Rockville, Maryland, USA

Sandra S. Richter, MD, D(ABMM)
University of Iowa Carver College of
Medicine
Iowa City, Iowa, USA

Flavia Rossi, MD
University of Sao Paulo
Sao Paulo, Brazil

Dale A. Schwab, PhD, D(ABMM)
Quest Diagnostics, Nichols Institute
San Juan Capistrano, California, USA

Jana M. Swenson, MMSc
Centers for Disease Control and
Prevention
Atlanta, Georgia, USA

Fred C. Tenover, PhD, D(ABMM)
Cepheid
Sunnyvale, California, USA

Joseph G. Toerner, MD, MPH
FDA Center for Drug Evaluation and
Research
Silver Spring, Maryland, USA

Hui Wang, PhD
Peking Union Medical College Hospital
Beijing, China

Working Group on Fastidious Organisms

James H. Jorgensen, PhD
Chairholder
University of Texas Health Science
Center
San Antonio, Texas, USA

Janet A. Hindler, MCLS, MT(ASCP)
Vice-Chairholder
UCLA Medical Center
Los Angeles, California, USA

Kathryn Bernard, MS
Public Health Agency of Canada
Winnipeg, Manitoba, Canada

Diane M. Citron, M(ASCP)
R.M. Alden Research Laboratory
Culver City, California, USA

Franklin R. Cockerill, III, MD
Mayo Clinic College of Medicine
Rochester, Minnesota, USA

Thomas R. Fritsche, MD, PhD
Marshfield Clinic
Marshfield, Wisconsin, USA

Guido Funke, MD
Gartner & Colleagues Laboratories
Weingarten, Germany

Henry Heine, PhD
Ordway Research Institute, Inc.
Albany, New York, USA

Patrick McDermott, PhD
FDA Center for Veterinary Medicine
Laurel, Maryland, USA

Jean B. Patel, PhD, D(ABMM)
Centers for Disease Control and
Prevention
Atlanta, Georgia, USA

Paul C. Schreckenberger, PhD,
D(ABMM), F(AAM)
Loyola University Medical Center
Maywood, Illinois, USA

John D. Turnidge, MD
SA Pathology at Women's and
Children's Hospital
North Adelaide, Australia

David F. Welch, PhD, D(ABMM)
University of Texas Southwestern
Medical Center
Dallas, Texas, USA

Advisors

Paul G. Ambrose, PharmD, FIDSA
ICPD/Ordway Research
Latham, New York, USA

Anton F. Ehrhardt, PhD
Cubist Pharmaceuticals, Inc.
Lexington, Massachusetts, USA

Frederic J. Marsik, PhD, ABMM
FDA Center for Drug Evaluation and
Research
Silver Spring, Maryland, USA

Jana M. Swenson, MMSc
Centers for Disease Control and
Prevention
Atlanta, Georgia, USA

Advisors (Continued)

Fred C. Tenover, PhD, D(ABMM)
Cepheid
Sunnyvale, California, USA

Mary K. York, PhD, ABMM
MKY Microbiology Consulting
Walnut Creek, California, USA

Staff

Clinical and Laboratory Standards Institute
Wayne, Pennsylvania, USA

Lois M. Schmidt, DA
Vice President, Standards Development

Tracy A. Dooley, BS, MLT(ASCP)
Staff Liaison

Melissa A. Lewis, ELS
Editorial Manager

Contents

Abstract.....i

Committee Membership..... iii

Foreword.....xi

1 Scope.....1

2 Introduction.....1

 2.1 Resistance Mechanisms in Gram-Positive Rods.....2

 2.2 Resistance in Infrequently Isolated or Fastidious Gram-Positive Cocci.....2

 2.3 Infrequently Isolated Nonfastidious Gram-Negative Rods.....2

 2.4 Fastidious Gram-Negative Rods.....2

 2.5 *Moraxella catarrhalis*.....3

 2.6 Potential Bacterial Agents of Bioterrorism.....3

 2.7 The Development of Interpretive Criteria or Breakpoints.....3

3 Standard Precautions.....4

4 Terminology.....4

 4.1 A Note on Terminology.....4

 4.2 Definitions.....4

 4.3 Abbreviations and Acronyms.....5

5 Indications for Performing Susceptibility Tests.....5

6 Methods for Dilution Antimicrobial Susceptibility Testing of Infrequently Isolated or Fastidious Bacteria.....6

 6.1 Selection of Antimicrobial Agents.....6

 6.2 Antimicrobial Agents.....6

 6.3 Interpretive Categories.....7

7 Methods for Antimicrobial Disk Diffusion Susceptibility Testing of Infrequently Isolated or Fastidious Bacteria.....7

8 Therapy-Related Comments.....7

9 Quality Control.....7

 9.1 Minimum Laboratory Requirements for Testing Infrequently Isolated or Fastidious Bacteria.....8

10 Detection of Resistance to Some β -Lactams by a Direct β -Lactamase Test.....8

Table 1. *Abiotrophia* spp. and *Granulicatella* spp. (Formerly Known as Nutritionally Deficient or Nutritionally Variant Streptococci)—Information and Interpretive Criteria for Broth Microdilution Susceptibility Testing..... 10

Table 2. *Aeromonas* spp. (Includes Members of *A. caviae* Complex, *A. hydrophila* Complex, and *A. veronii* Complex) and *Plesiomonas shigelloides*—Information and Interpretive Criteria for Broth Microdilution and Disk Diffusion Susceptibility Testing..... 12

Contents (Continued)

Table 3. *Bacillus* spp. (Not *B. anthracis*)—Information and Interpretive Criteria for Broth Microdilution Susceptibility Testing 14

Table 4. *Campylobacter jejuni/coli*—Information and Interpretive Criteria for Broth Microdilution and Disk Diffusion Susceptibility Testing 16

Table 5. *Corynebacterium* spp. (Including *C. diphtheriae*) and Coryneforms^a—Information and Interpretive Criteria for Broth Microdilution Susceptibility Testing 18

Table 6. *Erysipelothrix rhusiopathiae*—Information and Interpretive Criteria for Broth Microdilution Susceptibility Testing 20

Table 7. HACEK Group: *Aggregatibacter* spp. (formerly *Haemophilus aphrophilus*, *H. paraphrophilus*, *H. segnis*, and *Actinobacillus actinomycetemcomitans*), *Cardiobacterium* spp., *Eikenella corrodens*, and *Kingella* spp.—Information and Interpretive Criteria for Broth Microdilution Susceptibility Testing 22

Table 8. *Helicobacter pylori*—Interpretive Criteria for Agar Dilution Susceptibility Testing..... 24

Table 9. *Lactobacillus* spp.—Information and Interpretive Criteria for Broth Microdilution Susceptibility Testing..... 26

Table 10. *Leuconostoc* spp.—Information and Interpretive Criteria for Broth Microdilution Susceptibility Testing..... 28

Table 11. *Listeria monocytogenes*—Information and Interpretive Criteria for Broth Microdilution Susceptibility Testing..... 29

Table 12. *Moraxella catarrhalis*—Information and Interpretive Criteria for Broth Microdilution and Disk Diffusion Susceptibility Testing 30

Table 13. *Pasteurella* spp.—Information and Interpretive Criteria for Broth Microdilution and Disk Diffusion Susceptibility Testing..... 32

Table 14. *Pediococcus* spp.—Information and Interpretive Criteria for Broth Microdilution Susceptibility Testing..... 34

Table 15. *Vibrio* spp. (including *V. cholerae*)—Information and Interpretive Criteria for Broth Microdilution and Disk Diffusion Susceptibility Testing 36

Table 16. Potential Bacterial Agents of Bioterrorism: *Bacillus anthracis*, *Yersinia pestis*, *Burkholderia mallei*, *Burkholderia pseudomallei*, *Francisella tularensis*, and *Brucella* spp.—Interpretive Criteria for Broth Microdilution Susceptibility Testing 38

Table 17. Summary of Testing Conditions and Quality Control Recommendations for Infrequently Isolated or Fastidious Bacteria..... 42

Table 18. MIC: Quality Control Ranges for Nonfastidious Organisms (Unsupplemented Cation-Adjusted Mueller-Hinton Medium) 44

Table 18A. MIC: Quality Control Ranges for Broth Microdilution Methods (Cation-Adjusted Mueller-Hinton Broth With Lysed Horse Blood [2.5% to 5% v/v])..... 45

Contents (Continued)

Table 18B. MIC: Quality Control Ranges for *Campylobacter jejuni* (Broth Microdilution Method) (Cation-Adjusted Mueller-Hinton Broth With Lysed Horse Blood [2.5% to 5% v/v]).....46

Table 18C. MIC: Quality Control Ranges for Agar Dilution Methods (Mueller-Hinton Agar With Aged [≥ 2-Week-Old] Sheep Blood)47

Table 18D. MIC: Quality Control Ranges for Broth Microdilution Method (Cation-Adjusted Mueller-Hinton Broth + 2% Defined Growth Supplement^a)47

Table 18E. MIC: Quality Control Ranges for Broth Microdilution Methods (Brucella Broth Without Supplements Adjusted to pH 7.1 ± 0.1)48

Table 19. Disk Diffusion: Quality Control Ranges for Nonfastidious Organisms (Unsupplemented Mueller-Hinton Medium).....49

Table 19A. Disk Diffusion: Quality Control Ranges for Fastidious Organisms (Mueller-Hinton Medium With 5% Sheep Blood).....50

Glossary I (Part 1). β-Lactams: Class and Subclass Designation and Generic Name.....51

Glossary I (Part 2). Non-β-lactams: Class and Subclass Designation and Generic Name52

Glossary II. Abbreviations/Routes of Administration/Drug Class for Antimicrobial Agents Listed in M100-S2053

References.....56

Additional References.....58

Summary of Consensus Comments and Subcommittee Responses.....71

Summary of Delegate Comments and Subcommittee Responses.....72

The Quality Management System Approach.....76

Related CLSI Reference Materials77

Foreword

This document was developed for the purpose of providing guidance to clinical or public health microbiology laboratories regarding the performance of standardized susceptibility testing, when needed, of infrequently isolated or fastidious bacteria that are not presently included in CLSI documents M02¹ or M07.² *Helicobacter pylori*, *Vibrio cholerae*, and several potential agents of bioterrorism were moved from CLSI documents M02,¹ M07,² and M100³ to this document because they are fastidious or infrequently encountered in most microbiology laboratories. Some of the organisms included herein are aerobic gram-negative bacilli that are not members of the family *Enterobacteriaceae* but may be tested by the standard CLSI broth microdilution or disk diffusion methods in the same manner as the much more common *Enterobacteriaceae* isolates. Some aerobic gram-positive cocci and bacilli that are encountered periodically by clinical laboratories can likewise be tested reliably by the standard CLSI minimal inhibitory concentration (MIC) or disk diffusion test methods in a manner analogous to *Staphylococcus* or *Enterococcus* spp. In addition, several genera of fastidious gram-positive and gram-negative bacteria can be tested in the same manner as the streptococci, using blood-supplemented Mueller-Hinton media. For the purpose of this document, the term *fastidious* is used to describe bacteria that require media supplemented with blood or blood components and that possibly need an atmosphere other than ambient air (eg, with 5% CO₂) for acceptable growth. Because the standard CLSI media, reagents, and procedures can be used to test the organisms included in this guideline, the quality control procedures, strains, and acceptable zone diameter and MIC limits that have been established through previous rigorous studies can be used for tests with the less common organisms that are included in this document. The working group used a thorough search of the published literature in conjunction with the clinical experience of the members to apply or adapt interpretive criteria or breakpoints from other organisms that could best be applied to the interpretation of tests of the less common organisms in this document. Users of the guideline should be aware that the very extensive microbiological, clinical, and pharmacodynamic databases normally employed for setting breakpoints by CLSI did not exist for the collection of “orphan” organisms described in this document.

Interpretive breakpoints for cefazolin and for ertapenem, imipenem, and meropenem for the *Enterobacteriaceae* were voted to be changed by the Subcommittee on Antimicrobial Susceptibility Testing subsequent to final approval of this edition of M45. It is anticipated that those modified breakpoints will be adopted for use with *Aeromonas* spp. and *Vibrio* spp. in the next edition of M45 or possibly in a future supplement.

It is important for users of M45-A2 to recognize that commercial susceptibility testing devices are not addressed in this guideline. The methods described herein are generic reference procedures that can be used for routine susceptibility testing by clinical laboratories, or that can be used by clinical laboratories to evaluate commercial devices for possible routine use. Results generated by reference methods, such as those contained in CLSI documents, may be used by regulatory authorities to evaluate the performance of commercial systems as part of the approval process. Clearance by a regulatory authority indicates that the commercial susceptibility testing device provides susceptibility results that are substantially equivalent to results generated using the reference methods for the organisms and antimicrobial agents described in the manufacturer’s approved package insert. Some laboratories could find that a commercial dilution, antibiotic gradient, colorimetric, turbidimetric, fluorometric, or other method is suitable for selective or routine use.

Key Words

Agar dilution, antimicrobial agent, antimicrobial susceptibility, broth dilution, disk diffusion, microdilution, minimal inhibitory concentration (MIC), susceptibility testing

Updated Information in This Edition

Below is a summary of the changes in this document, which supersede the information presented in the previous edition of M45. The list includes “major” changes that appear for the first time in this edition of M45, or were modified since publication of M45-A. Other minor or editorial changes that were made to the general formatting are not listed here.

Foreword

Added paragraph from current edition of M100 related to using commercial systems vs CLSI reference methods (p. xi).

Section 1, Scope

Noted that testing of *Haemophilus* included in M100 relates to *H. influenzae* and *H. parainfluenzae* only (p. 1).

Section 2, Introduction

Updated HACEK group designation for *Aggregatibacter* (formerly *Actinobacillus*) (p. 1).

Section 4.2, Definitions

Added definitions for susceptible, intermediate, resistant, and nonsusceptible (p. 4).

Section 4.3, Abbreviations and Acronyms

Added a list of abbreviations and acronyms used in the document (p. 5).

Section 6.3, Interpretive Categories

Deleted only “S” criteria box because the definition of “nonsusceptible” is now in the list of definitions.

Section 9, Quality Control

Expanded statement about selecting quality control strains (p. 7).

Tables 1 through 19A

General

Modified therapy (Rx) comment for rifampin (Tables 3, 5, 7, and 12) (pp. 14, 18, 22, and 30).

Table 2, *Aeromonas* spp. and *Plesiomonas shigelloides*

Clarified incubation conditions for disk diffusion and MIC testing (p. 12).

Added new (revised) breakpoints for cefazolin, cefotaxime, ceftazidime, ceftriaxone, and aztreonam. Also added dosage regimens on which the new breakpoints are based (p. 12).

Table 3, *Bacillus* spp. (not *B. anthracis*)

Added fluoroquinolones to the agents to consider for primary testing box (p. 14).

Table 4, *Campylobacter jejuni/coli*

Clarified incubation conditions for disk diffusion and MIC testing (p. 16).

Added azithromycin and clarithromycin to the examples indicating macrolide resistance (p. 16).

Table 5, *Corynebacterium* spp.

Modified vancomycin breakpoints (p. 18).

Clarified scope of recommendations that apply to *Corynebacterium* spp. and other coryneforms including the genera *Arcanobacterium*, *Brevibacterium*, *Cellulomonas*, *Dermabacter*, *Leifsonia*, *Microbacterium*, *Oerskovia*, *Rothia*, and *Turicella* (p. 19).

Table 7, HACEK Group

Updated HACEK group designation for *Aggregatibacter* (formerly *Actinobacillus*) (p. 22).

Table 8, *Helicobacter pylori*

Imported table from M100-S20 (p. 24).

Table 9, *Lactobacillus* spp.

Added breakpoints for daptomycin and linezolid (p. 26).

Added intermediate and resistant breakpoints for imipenem (p. 26).

Modified breakpoints for clindamycin and vancomycin (p. 26).

Added comment to ampicillin regarding combined therapy with a penicillin and an aminoglycoside for treatment of serious infections (p. 26).

Updated Derivation of Interpretive Criteria section (p. 27).

Table 10, *Leuconostoc* spp.

Added comment regarding combined therapy with a penicillin and an aminoglycoside for treatment of serious infections (p. 28).

Table 12, *Moraxella catarrhalis*

Modified MIC breakpoints for amoxicillin-clavulanic acid ("S" only), azithromycin, clarithromycin, and erythromycin (p. 30).

Added disk diffusion breakpoints for amoxicillin-clavulanic acid, azithromycin, clarithromycin, erythromycin, tetracycline, and trimethoprim-sulfamethoxazole (p. 30).

Updated Derivation of Interpretive Criteria section (p. 31).

Table 13, *Pasteurella* spp.

Clarified incubation conditions for disk diffusion and MIC testing (p. 32).

Table 15, *Vibrio* spp.

Imported table from M100-S20 (p. 36).

Clarified incubation conditions for disk diffusion and MIC testing (p. 36).

Listed agents to consider for primary testing for *Vibrio* spp. and *V. cholerae* (p. 36).

Added MIC breakpoints for azithromycin for *V. cholerae* (p. 37).

Updated Derivation of Interpretive Criteria section (p. 37).

Table 16, Potential Bacterial Agents of Bioterrorism

Imported table from M100-S20 (p. 38).

Added agents to consider for primary testing for *Brucella* and *Francisella* (p. 38).

Table 17, Summary of Testing Conditions and Quality Control

Added *Helicobacter pylori*, *V. cholerae*, and potential agents of bioterrorism (pp. 42 and 43).

Quality Control Tables

Table 18

Added ranges for ampicillin and piperacillin for *E. coli* ATCC® 35218 (p. 44).

Table 18A

Added ranges for amoxicillin for *E. coli* ATCC® 35218 (p. 45).

Table 18B

Imported *Campylobacter* quality control from M100-S20 (p. 46).

Table 18C

Imported *Helicobacter* quality control from M100-S20 (p. 47).

Table 18D

Imported potential bacterial agents of bioterrorism quality control from M100-S20 (p. 47).

Table 19

Added ranges for azithromycin, clarithromycin, and erythromycin for *S. aureus* ATCC® 25923 (p. 49).

Glossaries

Glossary I – Added new antimicrobial subclass for ceftaroline and ceftobiprole (p. 51).

Glossaries I and II – Added razupenem to carbapenem subclass (p. 51).

Added sulopenem to penem subclass (p. 51).

Added linopristin-flopristin to streptogramin class (p. 52).

Added mupirocin to pseudomonic acid class (p. 52).

CLSI Subcommittee on Antimicrobial Susceptibility Testing Mission Statement

The CLSI Subcommittee on Antimicrobial Susceptibility Testing is composed of representatives from the professions, government, and industry, including microbiology laboratories, government agencies, health care providers and educators, and pharmaceutical and diagnostic microbiology industries. Using the CLSI voluntary consensus process, the subcommittee develops standards and guidelines that promote accurate antimicrobial susceptibility testing and appropriate reporting.

The mission of the CLSI Subcommittee on Antimicrobial Susceptibility Testing is to:

- Develop standard reference methods for antimicrobial susceptibility tests.
- Provide quality control parameters for standard test methods.
- Establish interpretive criteria for the results of standard antimicrobial susceptibility tests.
- Provide suggestions for testing and reporting strategies that are clinically relevant and cost-effective.
- Continually refine standards and optimize the detection of emerging resistance mechanisms through the development of new or revised methods, interpretive criteria, and quality control parameters.
- Educate users through multimedia communication of standards and guidelines.
- Foster a dialogue with users of these methods and those who apply them.

The ultimate purpose of the subcommittee's mission is to provide useful information to enable laboratories to assist the clinician in the selection of appropriate antimicrobial therapy for patient care. The standards and guidelines are meant to be comprehensive and to include all antimicrobial agents for which the data meet established CLSI guidelines. The values that guide this mission are quality, accuracy, fairness, timeliness, teamwork, consensus, and trust.

Methods for Antimicrobial Dilution and Disk Susceptibility Testing of Infrequently Isolated or Fastidious Bacteria; Approved Guideline—Second Edition

1 Scope

CLSI documents M02,¹ M07,² and M100³ describe standardized methods and interpretive criteria for antimicrobial susceptibility testing of common aerobic bacteria, including some fastidious organisms. However, there are a number of less frequently encountered or fastidious bacteria that are not addressed in those CLSI documents. Some are organisms that may cause serious infections, infections associated with trauma and environmental contamination, or device-associated infections in immunocompromised or postsurgical patients. These latter organisms are addressed in this guideline with the goal of providing recommendations for clinical microbiology laboratories on how and when to determine the susceptibility of these diverse organisms. This edition of the guideline also includes some fastidious or unusual organisms, including those potentially associated with bioterrorism, which were previously included in CLSI document M100.³

2 Introduction

Organisms that previously lacked defined methods for susceptibility testing and interpretive criteria included various coryneform bacteria, *Bacillus* spp. (other than *B. anthracis*), *Abiotrophia* and *Granulicatella* spp., several genera of gram-positive bacteria with intrinsic glycopeptide resistance (eg, *Erysipelothrix* spp., *Lactobacillus* spp., *Leuconostoc* spp., and *Pediococcus* spp.), as well as several species of fastidious gram-negative bacteria (eg, HACEK group organisms and *Pasteurella* spp.). In addition, more detailed guidance for test performance and interpretation were needed, especially breakpoints for *Listeria* spp., *Aeromonas* spp., *Plesiomonas* sp., *Vibrio* spp., *Moraxella catarrhalis*, and *Campylobacter* spp. The lack of test methods or interpretive criteria made it difficult to assess the frequency of acquired resistance in these less frequently isolated or fastidious organisms and discouraged the testing of individual patient isolates by clinical laboratories. However, concerns had been raised that resistance exists in some of these organisms, and that laboratories should be prepared to test them when appropriate.^{4,5}

Because infections due to organisms addressed in M45 occur less frequently than many of the organisms presently covered in CLSI documents M02¹ and M07,² and because of the fact that many of the antimicrobial agents of interest have been marketed for a number of years, it is not reasonable to expect the intensive CLSI document M23⁶ specified studies to be conducted on this special group of organisms. Instead, the goal of this document is to recommend test conditions and interpretive criteria based on a careful review of published microbiological data (distributions of minimal inhibitory concentrations [MICs]), limited animal model studies, the extant clinical literature regarding therapy for these organisms, and in a few instances, a review of existing pharmacokinetic data on the drugs of interest. In some cases, limited *in vitro* studies were performed.

This edition of M45 includes several potential bacterial agents of bioterrorism that could be encountered initially by clinical microbiology laboratories and that should be forwarded to appropriate reference or public health laboratories for identification, confirmation, and possible susceptibility testing. The procedures included in this document are intended for use by those reference or public health laboratories.

It is hoped that this CLSI guideline will assist clinical microbiology laboratories in determining an approach for testing these unusual organisms that is relevant to their individual practice settings.